Why did Caladrius Biosciences Inc. (CLBS) stock perform well on Tuesday?

CLBS Stock
CLBS Stock

Caladrius Biosciences Inc. (CLBS) shares soared 11.65% in after-hours on Tuesday, January 04, 2021, and closed at $1.15. Even in the regular trading session, CLBS’s stock gained 15.86%. CLBS shares have fallen 34.81% over the last 12 months, and they have moved up 22.60% in the past week. Over the past three months, the stock has lost 10.43%, while over the past six months, it has declined 30.41%.

Let’s briefly discuss its recent news and developments.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


>> 7 Top Picks for the Post-Pandemic Economy << 

CLBS participation in the upcoming conferences

Caladrius Biosciences, Inc. will participate virtually in H.C. Wainwright BioConnect Conference to be held on January 10-13, 2022.

Read More

CLBS will also participate in Biotech Showcase which is scheduled for January 10–12, 2022, and January 17–19, 2022.

At both events, President and CEO, David J. Mazzo, Ph.D., will present the company.

CLBS latest financial results

On November 04, 2021, Caladrius Biosciences, Inc. (CLBS) announced financial results for the three and nine months ended September 30, 2021.

Q3 2021 financial highlights

  • CLBS reported no revenue for the third quarter of 2021.
  • In Q3 2021, Research and development expenses were approximately $4.1 million compared to $3.0 million for the three months ended September 30, 2020.
  • General and administrative expenses were approximately $2.8 million for Q3 2021, compared to $2.3 million for Q3 2020.
  • It suffered a net loss of $6.9 million in Q3 2021 compared to a net loss of $5.3 million in Q3 2020.
  • The company ended the third quarter with cash, cash equivalents, and marketable securities of approximately $100.1 million.

CLBS new appointment

On September 01, 2021, Caladrius Biosciences, Inc. (CLBS) announced the appointment of Dr. Kristen K. Buck as the Company’s Chief Medical Officer (CMO).

Dr. Buck has extensive drug development experience in multiple therapeutic indications including cardiovascular/metabolic, rare diseases, gastrointestinal, neuroscience, oncology, immunology, and women’s health. She recently worked at ICON as its CMO.


Well, there is no significant news or development available to justify its exceptional positive performance on Tuesday. We are not sure how it will commence trading on Wednesday.

>> 7 Top Picks for the Post-Pandemic Economy << 

About the company

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. The Company’s current product candidates include CLBS16, for the treatment of coronary microvascular dysfunction, CLBS12 (HONEDRA® in Japan), and Buerger’s Disease in the U.S.


Please enter your comment!
Please enter your name here